Skip to main content

Congenital Heart Disease in Children

0
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Baxter
BaxterCosta Rica - Cartago
1 program
BAX602N/A
Baxter International
1 program
BAX602N/A1 trial
Active Trials
NCT05647161Active Not Recruiting34Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Baxter InternationalBAX602

Clinical Trials (1)

Total enrollment: 34 patients across 1 trials

BAX602 in Preventing the Adhesion Around Great Cardiac Vessels in Pediatric Patients With Congenital Heart Disease Undergoing Re-do Open Heart Surgery (Japan Trial)

Start: Dec 2022Est. completion: Dec 202534 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.